Literature DB >> 1742894

Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy.

M Miyaguchi1, J Olofsson, H B Hellquist.   

Abstract

The expression of EGFR was determined immunohistochemically in two groups of patients with glottic carcinoma, one that recurred after a full course of radiotherapy and one that did not. Using a 4-graded scale (-,+,++, ) 80% (12/15) of the recurrent carcinomas had a staining intensity and proportion of stained cells of ++ or more. The same figure for non-recurrent carcinomas was 39% (7/18). The difference is statistically significant (chi-squared with Yates' correction, P less than 0.05). The results indicate that an increased expression of EGFR may influence the rate of recurrence of glottic squamous cell carcinoma after radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742894     DOI: 10.1111/j.1365-2273.1991.tb01041.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  14 in total

1.  Potential biomarkers for radiosensitivity in head and neck cancers.

Authors:  Sherly Pardo-Reoyo; J L Roig-Lopez; Eddy S Yang
Journal:  Ann Transl Med       Date:  2016-12

2.  Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.

Authors:  Yukihiro Hiraishi; Takeshi Wada; Ken Nakatani; Kenji Negoro; Shigeyuki Fujita
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

Review 3.  EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.

Authors:  Kyle C Cuneo; Mukesh K Nyati; Dipankar Ray; Theodore S Lawrence
Journal:  Pharmacol Ther       Date:  2015-07-21       Impact factor: 12.310

4.  Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.

Authors:  Wen-Yen Huang; Yee-Min Jen; Chang-Ming Chen; Yu-Fu Su; Chun-Shu Lin; Yaoh-Shiang Lin; Ying-Nan Chang; Hsing-Lung Chao; Kuen-Tze Lin; Li-Ping Chang
Journal:  Radiat Oncol       Date:  2010-05-15       Impact factor: 3.481

5.  Prognostic significance of epidermal growth factor receptor in squamous cell carcinoma of the maxillary sinus.

Authors:  M Miyaguchi; S Sakai; J Olofsson; H Kuwabara; H Sakamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

6.  Expression of epidermal growth factor receptor in the inverted papilloma and squamous cell carcinoma of nasal cavity.

Authors:  Jiung-Chih Chao; Sheen-Yie Fang
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-01-30       Impact factor: 2.503

7.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

Authors:  J R Grandis; S D Drenning; A Chakraborty; M Y Zhou; Q Zeng; A S Pitt; D J Tweardy
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

8.  A correlation of argyrophilic nucleolar organizer regions with prognoses in patients with maxillary sinus squamous cell carcinoma.

Authors:  M Miyaguchi; T Kawahara; S Sakai; H Kuwabara; H Sakamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

9.  EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.

Authors:  Eric L Abhold; Alan Kiang; Elham Rahimy; Selena Z Kuo; Jessica Wang-Rodriguez; Jay Patrick Lopez; Katherine J Blair; Michael Andrew Yu; Martin Haas; Kevin T Brumund; Xabier Altuna; Andrew Patel; Robert A Weisman; Weg M Ongkeko
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

10.  Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.

Authors:  David Azria; Frederic Bibeau; Nicolas Barbier; Abderrahim Zouhair; Claire Lemanski; Philippe Rouanet; Marc Ychou; Pierre Senesse; Mahmut Ozsahin; André Pèlegrin; Jean-Bernard Dubois; Simon Thèzenas
Journal:  BMC Cancer       Date:  2005-06-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.